Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was ...

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

Adcendo will sponsor the Phase Ib clinical trial, and MSD will provide pembrolizumab.

Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

Merck anticipates its 2026 revenue will come in between $65.8 billion and $67 billion, narrowing the low-end of that range from $65.5 billion. The company also expects adjusted earnings to be between ...

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...

Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Tuesday that its antibody-drug conjugate Padcev extended survival when combined with the cancer immunotherapy ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...